Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Scientific decision criteria are fundamentally similar between biotech startups and large pharma. The stark difference in decision speed is not analytical depth, but the bureaucracy of managing competing portfolio opportunities across multiple executive approval layers.

Related Insights

Large pharmaceutical corporations possess the capital to advance dozens of therapeutic areas simultaneously, but small biotechs achieve velocity through strict specialization. Startups move faster through necessity by focusing their entire workforce on a single clinical challenge, feeding large pharma pipelines through partnerships.

Hervé Hoppenot rejects the notion that large organizations are inherently slow. He asserts that bureaucracy stems from a leadership failure to foster rapid decision-making, not from size itself. He believes large companies can be as agile as small ones if leaders actively break the bureaucracy.

Erik van den Berg asserts that the primary value of biotech leadership is making decisions with limited information. Because time is the most critical resource, delaying decisions is not a neutral act of caution. It actively wastes money and increases the overall cost of investment and drug development.

A seasoned pharma exec describes the transition to biotech, highlighting that the reduced complexity and faster pace are not just efficient but 'invigorating.' This speed allows for instantaneous, data-driven decisions on the fly, empowering teams to move much more quickly toward clinical goals and patient impact compared to the complex layers of large pharma.

A major source of unproductivity in drug development isn't the time spent reaching a clinical milestone. Instead, it's the 'white space' after data is received—the delay in analyzing results and making a firm go/no-go decision, which stalls the entire program.

In biotech, early data is often ambiguous. Instead of judging programs on potential, leaders must prioritize based on the time and capital required to reach a clear 'yes' or 'no' outcome. Indefinite 'gray zone' projects drain resources that could fund a winner.

While startups must be nimble, analytical processes from large corporations are invaluable. The key is applying the same rigorous thinking to decision-making but compressing the timeline. Having prior experience with similar situations allows leaders to make informed choices more quickly.

The primary operational difference between biotech and big pharma isn't just budget size, but how resource constraints force radical prioritization. The entire biotech organization must align on three or four critical, needle-moving goals tied to the next financing catalyst, a level of focus often diffused in larger companies.

The transition from a resource-rich environment like Novartis to an early-stage biotech reveals a stark contrast. The unlimited access to a global organization is replaced by a total reliance on a small, nimble team where everyone must be multi-skilled and hands-on, a change even experienced executives find jarring.

M&A is often framed as a win, but it can be detrimental to patients. The acquisition of an aggressive, fast-moving biotech by a large pharma company can lead to slowed development timelines and more conservative regulatory strategies, ultimately delaying access to life-saving treatments.